Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden.
Hannah BowerThomas FrisellDaniela di GiuseppeBénédicte DelcoigneUlf LindströmCarl TuressonKaterina ChatzidionysiouElisabet LindqvistAnn KnightHelena Forsblad-d'EliaJohan AsklingPublished in: RMD open (2023)
As used in clinical practice, response and remission at 6 months with JAKis are higher than with TNFi. Among patients with risk factors of concern, effectiveness is similar or numerically further increased. For individualised benefit-to-risk ratios to guide treatment choice, safety and effectiveness in specific patient segments should be considered.